Sustained release pharmaceutical composition of solid medical material
Patent 4343789 Issued on August 10, 1982. Estimated Expiration Date: 
July 2, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 2, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesInventorsAssigneeApplicationNo. 06/165244 filed on 07/02/1980US Classes:514/356, C=O in a C(=O)O group (e.g., nicotinic acid, etc.)424/497, Containing solid synthetic polymers426/33, Isolated triglyceride other than milk derived426/80, Having flow compeller means, e.g., compressor, etc.426/81Tapered gathered closureExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmInternational ClassesA61K 9/14 (20060101)A61K 9/16 (20060101) A61K 31/44 (20060101) Foreign Application Priority Data1979-07-05 JPAbstractSustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).Other References
| |
